Clinical trial
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
NCT07319676 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
- Lead sponsor
- National University Hospital, Singapore
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 2, 2026
- Completion date
- October 31, 2040
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma refractory